Univariate Cox analysis of PFS and OS with adverse events in the anlotinib group
| AEs | Number | PFS (days) | OS (days) | HR | P value | ||
|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | ||||
| Oral mucositis | 0.368 | – | 0.009 | – | |||
| Yes No | 15 66 | 261 ± 40 131 ± 14 | – | (0.175, 0.776) | |||
| Leukopenia | 0.551 | – | 0.044 | – | |||
| Yes No | 19 62 | 210 ± 37 128 ± 12 | – | (0.308, 0.983) | |||
| Elevated NLR | 1.790 | – | 0.020 | – | |||
| Yes No | 30 51 | 106 ± 16 175 ± 19 | – | (1.096, 2.923) | |||
| Hypophosphatemia | 0.283 | – | 0.015 | – | |||
| Yes No | 8 73 | 293 ± 63 132 ± 13 | (0.102, 0.781) | ||||
| Hypercholesterolemia | – | 0.476 | – | 0.029 | |||
| Yes No | 20 61 | 414 ± 58 237 ± 19 | (0.244, 0.928) | ||||
| Elevated lipase | – | 2.214 | – | 0.040 | |||
| Yes No | 20 61 | 172 ± 35 311 ± 28 | (1.035, 4.738) | ||||
| Hypoproteinemia | – | 2.882 | – | 0.004 | |||
| Yes No | 10 71 | 133 ± 33 316 ± 27 | (1.396, 5.950) | ||||
| Elevated amylase | – | 3.745 | – | 0.008 | |||
| Yes No | 5 76 | 134 ± 19 307 ± 27 | (1.415, 9.909) | ||||
| Elevated GGT | 1.720 | 2.139 | 0.048 | 0.008 | |||
| Yes No | 21 60 | 107 ± 20 164 ± 18 | 180 ± 32 331 ± 30 | (1.005, 2.943) | (1.224, 3.738) | ||
“−” means this index is not a significant factor. AEs, adverse events; TSH, Thyroid stimulating hormone.